Market Place
Sourcing Support
AstraZeneca completes acquisition of Icosavax
21 Feb 2024 //
INDIAN PHARMA POST
AstraZeneca Buys into RSV Vaccine Market with Potential $1.1B Icosavax Purchase
13 Dec 2023 //
BIOSPACE
Icosavax Announces Positive Topline Interim Phase 2 Results for IVX-A12
12 Dec 2023 //
PRESS RELEASE
Icosavax Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Icosavax to Participate in the Jefferies London Healthcare Conference
08 Nov 2023 //
GLOBENEWSWIRE
Icosavax to Participate in Guggenheim Healthcare Talks 5th Annual INI Conference
31 Oct 2023 //
GLOBENEWSWIRE
Icosavax to Participate in Cantor Fitzgerald Global Healthcare Conference 2023
19 Sep 2023 //
GLOBENEWSWIRE
Icosavax Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121
08 Aug 2023 //
GLOBENEWSWIRE
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth
02 Jul 2023 //
YAHOO FINANCE
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
20 Jun 2023 //
GLOBENEWSWIRE
Icosavax pushes forward combo RSV-hMPV vaccine
23 May 2023 //
ENDPTS
Icosavax Announces Positive Topline Interim Phase 1 Results for IVX-A12
22 May 2023 //
PRESS RELEASE
Icosavax Announces Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12
22 May 2023 //
GLOBENEWSWIRE
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
22 May 2023 //
GLOBENEWSWIRE
Icosavax Reports 1Q 2023 Financial Results and Provides Corporate Update
10 May 2023 //
GLOBENEWSWIRE
Icosavax Reports 4Q and Full Reports 2022 FYR and Provides Corporate Update
30 Mar 2023 //
GLOBENEWSWIRE
Icosavax to Participate in the Upcoming Healthcare Conferences
28 Feb 2023 //
GLOBENEWSWIRE
Icosavax Granted FDA Fast Track Designation for IVX-A12
21 Feb 2023 //
GLOBENEWSWIRE
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
06 Jan 2023 //
GLOBENEWSWIRE
Have Insiders Sold Icosavax Shares Recently?
22 Dec 2022 //
SIMPLYWALL
Icosavax pushes forward with an RSV candidate after Covid-19 vaccine flop
14 Dec 2022 //
ENDPTS
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121
13 Dec 2022 //
GLOBENEWSWIRE
Icosavax to Participate in the Evercore ISI HealthCONx Conference
22 Nov 2022 //
GLOBENEWSWIRE
Icosavax Reports Third Quarter Financial Results and Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults
04 Oct 2022 //
GLOBENEWSWIRE
Icosavax Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Icosavax Announces Results from IVX-411 Drug Product Investigation
28 Jul 2022 //
GLOBENEWSWIRE
Icosavax to Participate in the William Blair Biotech Focus Conference
06 Jul 2022 //
GLOBENEWSWIRE
Icosavax says its RSV candidate passed early test
29 Jun 2022 //
ENDPTS
Icosavax`s Positive Topline Interim PI/Ib Results for IVX-121 Against RSV
28 Jun 2022 //
GLOBENEWSWIRE
Icosavax to Participate in the Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Icosavax Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Icosavax stock pops up 6% after insider buying
06 Apr 2022 //
SEEKING ALPHA
Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411
25 Mar 2022 //
GLOBENEWSWIRE
Icosavax to Participate in the Cowen 42nd Annual Health Care Conference
02 Mar 2022 //
GLOBENEWSWIRE
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
07 Jan 2022 //
GLOBENEWSWIRE
Icosavax Reports Second Quarter 2021 Financial Results
13 Sep 2021 //
GLOBENEWSWIRE
Icosavax Appoints Elizabeth Bekiro?lu to General Counsel
10 Sep 2021 //
GLOBENEWSWIRE
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against RSV
09 Sep 2021 //
GLOBENEWSWIRE
Icosavax Announces Closing of Initial Public Offering
02 Aug 2021 //
GLOBENEWSWIRE
Icosavax Announces Pricing of Upsized Initial Public Offering
29 Jul 2021 //
BUSINESSWIRE
Icosavax Announces Pricing of Upsized Initial Public Offering
29 Jul 2021 //
BUSINESSWIRE
Icosavax Appoints Thomas J. Russo Chief Financial Officer
10 Jun 2021 //
BUSINESSWIRE
Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate
08 Jun 2021 //
BUSINESSWIRE
Icosavax raises funding to advance RSV/hMPV vaccine programme
07 Apr 2021 //
PHARMACEUTICAL
Icosavax keeps up the excitement for its VLP `soccer balls,` the RA Capital
07 Apr 2021 //
ENDPTS
Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic
07 Apr 2021 //
FIERCEBIOTECH
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV
07 Apr 2021 //
BUSINESSWIRE
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV
06 Apr 2021 //
BUSINESSWIRE
Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 M
30 Oct 2020 //
BUSINESSWIRE
Icosavax Launches with $51 Million Series
03 Oct 2019 //
BUSINESSWIRE
